128 related articles for article (PubMed ID: 8412208)
1. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1993; 17F():37-48. PubMed ID: 8412208
[TBL] [Abstract][Full Text] [Related]
2. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
3. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
[TBL] [Abstract][Full Text] [Related]
4. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.
Trock BJ
Urology; 2001 Apr; 57(4 Suppl 1):241-7. PubMed ID: 11295636
[TBL] [Abstract][Full Text] [Related]
5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
6. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
7. Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action.
Boone CW; Kelloff GJ; Freedman LS
J Cell Biochem Suppl; 1993; 17G():14-25. PubMed ID: 8007692
[TBL] [Abstract][Full Text] [Related]
8. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
9. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy.
Boone CW; Kelloff GJ; Steele VE
Cancer Res; 1992 Apr; 52(7):1651-9. PubMed ID: 1551096
[TBL] [Abstract][Full Text] [Related]
10. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
Proc Soc Exp Biol Med; 1997 Nov; 216(2):151-65. PubMed ID: 9349684
[TBL] [Abstract][Full Text] [Related]
11. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
12. The natural history of intraepithelial neoplasia: relevance to the search for intermediate endpoint biomarkers.
Boone CW; Kelloff GJ; Steele VE
J Cell Biochem Suppl; 1992; 16G():23-6. PubMed ID: 1469901
[TBL] [Abstract][Full Text] [Related]
13. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia.
Beenken SW; Huang P; Sellers M; Peters G; Listinsky C; Stockard C; Hubbard W; Wheeler R; Grizzle W
J Cell Biochem Suppl; 1994; 19():270-7. PubMed ID: 7823600
[TBL] [Abstract][Full Text] [Related]
14. Role of the pathologist in biomarker studies.
Wilkinson EJ; Hendricks JB
J Cell Biochem Suppl; 1995; 23():10-8. PubMed ID: 8747373
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
17. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
18. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
19. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
20. Development of chemopreventive agents for lung and upper aerodigestive tract cancers.
Kelloff GJ; Boone CW; Steele VK; Perloff M; Crowell J; Doody LA
J Cell Biochem Suppl; 1993; 17F():2-17. PubMed ID: 8412195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
